Chris Min, MD, PhD

K. Chris Min, MD PhD joined LGVN in April 2022. He is board certified neurologist and has over 20 yrs of exp in rsch in neuroscience, biochemistry and struct biology. Had clinical dev exp in both big pharma, with 8 yrs in early clinical dev, as well as biotech startups since 2018. While at Merck, he conducted the pivotal Ph1 clinical safety trial that led to the 2015 approval of Bridion™, a drug indicated for reversing neuromuscular blockade induced by rocuronium or vecuronium, typically during surgery. Bridion® was the 1st novel anesthesia product in over 2 decades. He served in senior roles at BlueRock ,Cerevel and Enterin Inc. previously conducting trials in Ph1 and Ph2 across multiple neurologic indications incl AD, PD and migraines. Prior to his industry exp, Dr. Min served as a rsch clinician, faculty, and attending at Columbia Univ Irv Med Ctr & Harlem Hosp. Earned an M.D. from Weill Medical of Cornell Univ, a Ph.D. in Biochem from Rockefeller Univ and BA Biochem Harvard.